Pharma & Biotech Events & Conferences
Refine Search
Pharmaceutical
Merck KGaA has outlined the data it will present at the 2019 European Society for Medical Oncology (ESMO) annual meeting, starting in Barcelona on Friday. 23 September 2019
Biotechnology
Swiss cancer giant Roche has outlined the data it intends to present at the upcoming annual meeting of the European Society for Medical Oncology (ESMO). 23 September 2019
Pharmaceutical
New York’s Pfizer will present data on 11 therapies in 22 types of cancer, at the European Society for Medical Oncology (ESMO) annual meeting, in Barcelona. 20 September 2019
Biotechnology
Bristol-Myers Squibb has outlined the data it will present at this year’s annual meeting of the European Society for Medical Oncology (ESMO), in Barcelona. 19 September 2019
Pharmaceutical
According to new data from the CONCLUDE head-to-head trial, Tresiba (insulin degludec) showed an overall lower risk of hypoglycemia, also known as a hypo or low blood sugar, at a significantly lower HbA1c, compared with insulin glargine U300 in adults with type 2 diabetes uncontrolled on basal insulin with or without oral anti-diabetic drugs (OADs). 19 September 2019
Biotechnology
Data presented in a symposium session at the annual meeting of the European Association for the Study of Diabetes (EASD) provide insights into imeglimin, an investigational type 2 diabetes medicine. 18 September 2019
Pharmaceutical
London-listed drugmaker GlaxoSmithKline will present data across nine tumor types at the upcoming annual meeting of the European Society for Medical Oncology Congress (ESMO). 17 September 2019
Pharmaceutical
At the upcoming annual meeting of the European Society for Medical Oncology (ESMO), UK-based drugmaker AstraZeneca will present data in 63 abstracts, including in Presidential Symposia across three cancer types. 16 September 2019
Pharmaceutical
Shares of Japan’s Daiichi Sankyo were up 1.2% at 6,889 yen by mid afternoon trading in Tokyo, after the company reported positive results with its already marketed Lixiana (edoxaban) at the ESC Congress 2019 taking place in Paris, France, and published in The Lancet. 4 September 2019
Biotechnology
Detailed results have been presented by The Medicines Company from the ORION-11 trial evaluating the efficacy, safety, and tolerability of inclisiran to decrease LDL-cholesterol (LDL-C) through twice-yearly dosing. 3 September 2019
Biotechnology
UK-based drugmaker AstraZeneca has presented detailed results from the Phase III DAPA-HF trial of Farxiga (dapagliflozin) at the ESC Congress 2019 in Paris. 3 September 2019
Biotechnology
Japan’s largest drugmaker Takeda Pharmaceutical announced updated results from its Phase IIIb/IV clinical trial for Adynovate (antihemophilic factor [recombinant], PEGylated) at the 27th Annual International Society on Thrombosis and Hemostasis Congress (ISTH), in Melbourne, Australia. 9 July 2019
Pharmaceutical
Results from two pediatric studies of Pradaxa (dabigatran etexilate mesylate) have been presented at the International Society on Thrombosis and Hemostasis (ISTH) 2019 Congress in Melbourne, Australia. 9 July 2019
Biotechnology
At the annual congress of the International Society on Thrombosis and Hemostasis (ISTH) in Australia, Swiss pharma giant Roche has announced new data for Hemlibra (emicizumab) across multiple pivotal studies in people with hemophilia A. 9 July 2019
Biotechnology
France’s Pierre Fabre and USA-based development partner Array BioPharma have announced positive interim analysis results from the Phase III BEACON CRC trial. 8 July 2019
Biotechnology
French biotech firm GamaMabs Pharma has announced positive clinical data from its Phase II study of murlentamab in metastatic colorectal cancer (mCRC), at the European Society of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, taking place in Barcelona, Spain. 5 July 2019
Biotechnology
Israel’s leading drugmaker Teva Pharmaceutical has presented data from exploratory endpoints from the Phase IIIb FOCUS trial of Ajovy (fremanezumab), at the annual congress of the European Academy of Neurology (EAN). 2 July 2019
Biotechnology
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
Pharmaceutical
Now that the warming Spanish sun has gone down on EULAR 2019, it’s worth considering what emerged of note from some of rheumatology’s leading players at the event in Madrid. 20 June 2019
Biotechnology
The flags have been furled, poster boards packed away, and ASCO planners are already getting ready for another year. Now, before attention turns to the next major event, we recap some of the key highlights and learnings from the industry’s preeminent cancer conference. 17 June 2019
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze